Purpose: Influence of benzodiazepine (midazolam)or cholinergic inhibitor (atropine or glycopyrrlate) on intra-operative body temperature remains unclear and controversial. This study compares intra-operative body temperature in 50 abdominal surgical patients under general anesthesia between the administration of midazolam and glycopyrrolate in combination, or glycopyrrolate alone. Methods: Patients who underwent abdominal surgery were recruited from September 2008 through October 2009 at Gachon University Gil hospital in Incheon. Core body temperature was measured in the right ear using a tympanic membrane thermometer at induction of general anesthesia and at 1 hr, 2 hr, and 3 hr after induction. Results: There were no differences in core body temperature at any measurement point between either patient group (F= 1.08, p= .377). Core body temperature decreased throughout the 3 hr after induction in both groups (F= 9.22, p< .001). Specially, core temperatures at induction of general anesthesia (p< .001), 1 hr (p< .001), 2 hr (p< .001), and 3 hr (p< .001) after induction were lower than before administration of midazolam and glycopyrrolate, or glycopyrrolate alone. Conclusion: We conclude that a cholinergic inhibitor (glycopyrrolate, 0.1 mg) therefore seems not to affect intra-operative body temperature of patients given a benzodiazepine (midazolam, 0.04 mg kg -1 ), and not to increase body temperature in patients not given a benzodiazepine during the 3 hr after the induction of general anesthesia. Intra-operative warming therefore is needed to prevent hypothermia in surgical patients who receive pre-operative administration of midazolam and/or glycopyrrolate.
INTRODUCTION
Hypothermia is de ned as having a core body temperature less than 36°C (Insler, O'Connor, Leventhal, Nelson, & Starr, 2000; Karalapillai & Story, 2008; Sessler, 2001) . Intra-operative hypothermia is a common perioperative complication of surgery in which body cavities are exposed to ambient temperature. e risk factors of intra-operative hypothermia include major surgery such as abdominal, thoracic, spine and hip arthroplastic operation, blood transfusion, duration of surgery >2-3 hr, combined epidural and general anesthesia, age >70 yr, low pre-operative body temperature, and an ambient temperature in the operating room < 21.3°C (Flores-Maldonado et al., 1997; Frank et al., 1992; Poveda, Galvão, & dos Santos, 2009 ). Intra-operative hypothermia increases the risk of surgical wound infection (Flores-Maldonado et al., 1997; Frank et al., 1992; Poveda, Galvão, & dos Santos, 2009 ), decreases immune responses (Matsui, Ishikawa, Takeuchi, Okabayashi, & Maekawa, 2006; Qadan et al., 2009) , impairs coagulation (Rohrer & Natale, 1992) , and stimulates cardiac arrhythmia (Frank et al., 1997) . A nurse anesthetist takes an important role in preventing intra-operative hypothermia.
Midazolam is a benzodiazepine class compound that is commonly administered for sedation. e association of midazolam and hypothermia has been studied since Irvine (1966) reported the death of an 84-yrold male patient due to accidental hypothermia a er administration of diazepam (another benzodiazepine). However, the data about accidental hypothermia have been equivocal. Taylor, Little, Nutt, and Sellars (1985) reported the hypothermic effect of a benzodiazepine on rodents, and Matsukawa et al. (1997) concluded that midazolam impeded thermoregulatory vasoconstriction and produced core-to-peripheral heat redistribution and hypothermia. In addition, Matsukawa et al. (2001) reported that cholinergic inhibitors (atropine or glycopyrrolate) were associated with an increase in core temperature of 0.3°C, while a combination of midazolam and atropine did not affect core temperature 30 min after administration. The authors concluded that cholinergic inhibitors opposed the thermoregulatory e ects of the benzodiazepine receptor agonist, preventing midazolam-induced core hypothermia in elderly patients. e net e ect is to leave core temperature unchanged.
On the other hand, Kurz et al. (1995) demonstrated that midazolam produced little impairment of thermoregulatory control. Moreover, Toyota, Sakura, Saito, Ozasa, and Uchida (2004) asserted that midazolam as premedication could reduce intra-operative heat loss. Furthermore, Park and Yoon (2007) reported that the combination of midazolam and glycopyrrolate decreased intra-operative core temperature by 0.3°C, even though the patients received warm fluid intravenously. In light of the studies by Kurz et al. (1995) , Toyota et al. (2004) and Park and Yoon (2007) , a benzodiazepine (midazolam) seems to attenuate, rather than produce, intra-operative hypothermia, and a cholinergic inhibitor (glycopyrrolate) seems not to prevent intra-operative hypothermia.
The relationship between intra-operative body temperature and a benzodiazepine or a cholinergic inhibitor still remains unclear and controversial. To prevent hypothermia during anesthesia, monitoring body temperature is an important role of the nurse anesthetist. The present study therefore compared intra-operative body temperature for 3 hr after induction of general anesthesia in a small group of Korean patients undergoing abdominal surgery. Patients were administered either midazolam and glycopyrrolate, or glycopyrrolate alone.
METHODS

Research design
This prospective research was conducted in Incheon, Korea, from September 2008 to October 2009.
Setting and samples
All participants were American Society of Anesthesiologists (ASA) physical status I (a normal healthy patient) or II (a patient with mild systemic disease), and were recruited by an advertisement posted from September 2008 through October 2009 at Gachon University Gil hospital.
All participants underwent elective abdominal surgery under general anesthesia. On the basis of previous studies, the risk factors for the development of hypothermia or decreased body temperature in the peri-operative period include low body mass index (BMI), low total body fat, low body surface area, ASA physical status III or IV, and a history of diabetic neuropathy (Kitamura, Hoshino, Kon, & Ogawa, 2000; Kongsayreepong et al., 2003; Kurz et al., 1995; Poveda et al., 2009; Yamakage et al., 2000) . In addition, thyroid disease a ects cardiovascular function or the balance of body heat, and Raynaud's disease leads to peripheral vasoconstriction. We therefore included patients with age >20 yr, BMI >18.5 kg m -2 , consciousness, and ASA class I or II, who were to be administered glycopyrrolate for premedication, and were to undergo anesthesia for more than 3 h. We excluded patients with a history of diabetes Figure. 1). Four patients were withdrawn from the study because they received a blood transfusion during their surgery; two of these patients belonged to the midazolam and glycopyrrolate group, and two to the glycopyrrolate group, respectively. e nal number of patients studied was 50; 25 of whom received midazolam and glycopyrrolate, and 25 glycopyrrolate alone.
Procedures
1)Recruitmentofsubjects e protocol was approved by the Ethics and Research Committee of
Gachon University Gil Hospital (IRB No: 200809-03-I008) . All abdominal surgical patients were fully informed about the purpose, nature, design and duration of the study during the pre-operative interview, and their written consent was then obtained.
2)AdministrationofMidazolamorglycopyrrolate
Midazolam (0.04 mg kg -1 ) or glycopyrrolate (0.2 mg) were administered intramuscularly to the patients in the ward 30 min before their transfer to the operating room.
3) Techniqueofgeneralanesthesiaandwarmingofpatients duringoperation
General anesthesia was performed with a standardized technique.
Each patient was administered intravenous propofol (1.5 mg kg . At the commencement of skin suture, the neuromuscular blockade was reversed with neostigmine (1.0 mg) and atropine (1.0 mg), and the trachea was extubated.
Power calculation
Effect size was calculated as 0.492 and 0.599 being based on the respective studies of Matsukawa et al. (2001 Matsukawa et al. ( , 2003 . With an e ect size of 0.492, an alpha of 0.05 and a power of 0.8, at least 25.4 study participants for each group were required for the present study to have statistically predictive power. With an effect size of 0.599, 17.2 study participants were required. Consequently, we selected a total of 50 surgical patients for this study, 25 subjects with administration of midazolam and glycopyrrolate, and 25 subjects with administration of glycopyrrolate alone.
Measurements
Demographic 
RESULTS
Demographic and physiologic characteristics
e results of the homogeneity test for the demographic and clinical physiological characteristics of the two groups are presented in Table 1 .
The Chi-square test for gender, ASA physical status, disease, and the type of operation showed no statistically signi cant di erences between the two groups (Table 1 ). In addition, age, pre-operative systolic blood pressure, heart beat, pre-operative TMT, ambient temperature in the operating room, duration of anesthesia, volume of irrigation uid for the abdominal cavity, and estimated blood loss showed no statistically significant differences between the two groups. Furthermore, BMI, BSA, LBM, and TBF for the two groups were similar. Pre-operative TMT was almost similar in both groups; 36.95°C in the group administered glycopyrrolate alone and 36.82°C in the group administered combination of midazolam and glycopyrrolate (t=1.69, p = .096).
Effect of midazolam or glycopyrrolate on TMT
e e ect of midazolam or glycopyrrolate on intra-operative TMT is 
Incidence of hypothermia for 3 hr after induction of general anesthesia
Incidence rate of hypothermia for 3 hr a er induction of general anesthesia is summarized in Table 3 . e incidence rate for hypothermia at 1 hr, 2 hr and 3 hr a er induction of general anesthesia was 34 %, 44%, and 60% in the entire group administered glycopyrrolate, or in the group administered combination of midazolam and glycopyrrolate, respectively.
DISCUSSION
Hypothermia is the most common intra-operative complication of general anesthesia. Previous studies reported a relationship between an- (44) 19 (76) 30 ( However, following the induction of anesthesia, TMT decreased continuously in both groups throughout the 3 hr post-induction period (F =127.6, p < .001). Specially, TMT at induction (p < .001), and at 1 hr (p < .001), 2 hr (p < .001), and 3 hr (p < .001) a er induction were lower than before administration of midazolam or glycopyrrolate in either group.
Although TMT in the glycopyrrolate group was slightly higher than in the midazolam and glycopyrrolate group, the differences were not statistically signi cant (F =3.57, p = .065).
TMT in the group administered glycopyrrolate was significantly greater than in the group administered midazolam and glycopyrrolate a er induction of anesthesia (p < .05). esthesia, heat redistribution and hypothermia (Matsukawa et al., 1995 (Matsukawa et al., , 1997 Taylor et al., 1985) . In addition, Matsukawa et al. (2001) reported that cholinergic inhibitors prevented midazolam-induced core hypothermia. However, the previous ndings have not been clari ed the relationship between intra-operative hypothermia, benzodiazepine and cholinergic inhibitors. The present study investigates the effect of premedication using benzodiazepine (midazolam) and cholinergic inhibitor (glycopyrrolate) on intra-operative body temperature for the 3 hr after the induction of general anesthesia in a small group of Korean patients undergoing abdominal surgery.
We observed a decrease in body temperature of 0. (2004) . While Toyota et al. (2004) maintained that premedication using midazolam increased slightly body temperature at 2 hr a er induction of general anesthesia, Matsukawa et al. (1997) and Sato et al. (2009) reported that midazolam as premedication significantly decreased core temperature. However, the decrease of body temperature in these studies may not be solely attributable to midazolam in certain aspects. Firstly, the decrease of core temperature reported by Matsukawa et al. (1997) and Sato et al. (2009) Toyota et al. (2004) , the data of Matsukawa et al. (1997) and Toyota et al. (2004) cannot be directly compared.
Nonetheless, a premedication dose of 0.04 mg kg -1 of midazolam seems not to lead to a decreased intra-operative body temperature.
In the present study, patients who received a combination of midazolam and glycopyrrolate had a slightly lower core temperature (0.1-0.2°C) throughout the 3 hr a er the induction of anesthesia than those who received glycopyrrolate alone, even though there was not a statistically signi cant di erence (p = .065) between the two groups. e di erence of pre-operative core body temperatures (36.95 and 36.82°C, respectively) might be attributable to intra-operative body temperature. Further studies concerning intra-operative hypothermia and administration of midazolam are needed.
While core body temperature in our study decreased by approximately 1.0°C during the first 2 hr after the induction of anesthesia, despite provision of intra-operative warming, Toyota et al. (2004) Kongsayreepong et al., 2003) . In addition, the ambient temperature of our study setting was lower by 1°C
(23.3°C) compared to that (24.4-24.7°C) in the study of Toyota et al. (2004) .
Incidence of hypothermia was 34%, 44%, and 60% at 1 hr, 2 hr, and 3 hr following induction of general anesthesia, despite the continuous provision of intra-operative warming using a circulating water mattress.
We therefore need to take other measures to maintain a body temperature greater than 36°C during anesthesia. Of course, a low ambient temperature leads to a decrease in core temperature (Kongsayreepong et al., 2003) . Although El-Gamal et al. (2000) proposed maintaining the ambient temperature of the operating room at 26°C to prevent intra-operative hypothermia, such an ambient temperature will make surgeons sweat and will lead to waste electricity. As an application of intravenous uid warming or skin surface warming failed to maintain intra-operative body temperature over 36°C (Park and Yoon, 2007) , we recommend the combined use of these two warming methods for prevention of intraoperative hypothermia in patients who undergo abdominal surgery lasting more than 2 hr. In addition, awareness of the complications arising from intra-operative hypothermia and a strict adherence to thermal monitoring can play an important role in prevention of peri-operative hypothermia.
e major limitation of this study is that it was not a clinical randomization trial, but was a prospective study, a condition imposed by the Institutional Review Board, due to ethical concerns associated with a randomized controlled trial. However, by matching age, gender, and ASA physical status, we ensured homogeneity of the demographic and physiological characteristics. Our findings therefore are applicable to the management of intra-operative hypothermia for patients undergoing abdominal surgery under general anesthesia.
CONCLUSION
We conclude that there is no di erence in intra-operative body temperature between patients administered a combination of midazolam ), and not to increase body temperature in patients not given a benzodiazepine during the 3 hr a er the induction of general anesthesia. Intra-operative warming therefore is needed to prevent hypothermia in surgical patients who receive pre-operative administration of midazolam and/or glycopyrrolate.
